Abstract:10544 Background: Screening the biomarkers from the cell-free DNA (cfDNA) of peripheral blood is a non-invasive and promising method for cancer diagnosis. Among diverse types of biomarkers, epigenetic biomarkers have been reported to be one of the most promising ones. Epigenetic modifications are widespread on the human genome and generally have strong signals due to the similar methylation patterns shared by adjacent CpG sites. Although some epigenetic diagnostic methods have been developed based on cfDNAs, few of them could be applied to pan-cancer and their sensitivities are barely satisfactory for early cancer detection. Methods: Targeted methylation sequencing was performed using our in-house-designed panel targeting regions with abundant cancer-specific methylation CpGs. The cfDNA samples from 80 healthy individuals and 549 cancer patients of 14 cancer types were separately sequenced. The dataset was randomly split into one discovery dataset and one validation dataset. Moreover, cfDNA samples from four cancer patients were diluted with the healthy cfDNAs to generate 12 in vitro simulated samples with low circulating tumor DNA (ctDNA) fraction. Additionally, DNAs extracted from 130 unmatched tumor formalin fixation and paraffin embedding (FFPE) samples of 10 cancer types were sequenced to screen the diagnostic biomarkers. Adjacent CpG sites were first merged into methylation-correlated blocks (MCB) according to their correlations of methylation levels in tumor DNAs. The MCBs with higher methylation levels in tumor DNAs than that of healthy cfDNAs (from the discovery dataset) were defined as our hypermethylation biomarkers. For each cfDNA sample, a hypermethylation score (HM-score) was computed to measure the overall methylation level difference of selected biomarkers. The performance of our method was evaluated with the real-world dataset, while the limit of detection was estimated using the simulated low-ctDNA samples. Results: Our model based on 37 hypermethylation MCB biomarkers achieved an area under the curve (AUC) of 0.89 and 0.86 in the real-world pan-cancer discovery and validation cfDNA datasets, respectively. Furthermore, the overall specificity and sensitivity are 100% and 76.19% in the discovery dataset, and 96.67% and 72.86% in the validation dataset. In the validation dataset, 28/40 (70%) of early-stage colorectal cancer patients and 10/20 (50%) of non-small-cell lung cancer patients were successfully diagnosed. Additionally, all the simulated samples with theoretical ctDNA factions over 0.5% were predicted as diseased, demonstrating the ability of our method to detect tumor signals at early stages. Conclusions: Our cfDNA-based epigenetic method outperforms currently available methods in various cancer types, and is promising to be applied to early-stage cancer detection and samples with low ctDNA fractions.

A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer

Early Detection of Non-Small Cell Lung Cancer with Novel 5-Hydroxymethylcytosine DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma

5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer

A 5-Hydroxymethylcytosine-based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: the METHOD-2 Study

Highly sensitive noninvasive early lung cancer detection using DNA methylation topology in sputum-derived epithelial cells

Blood-based DNA Methylation Panel for the Early Diagnosis of Lung Cancer

Early Non-Invasive Detection Of Stage La Lung Cancer Using Circulating Tumor Dna Methylation Haplotypes (Ctmdna) In Plasma.

Early detection of lung cancer using a panel of circulating cell-free DNA methylation biomarkers.

Ultrasensitive DNA Hypermethylation Detection Using Plasma for Early Detection of NSCLC: a Study in Chinese Patients with Very Small Nodules.

Accurate detection of early-stage lung cancer using a panel of circulating cell-free DNA methylation biomarkers

An Ultrasensitive Method for Noninvasive Pan-Cancer Early Detection Based on Targeted Methylation Sequencing of Cell-Free DNA.

Ultrasensitive DNA Hypermethylation Detection Using Plasma for Early Detection of NSCLC: A Validation Study in Chinese Patients.

Integrated 5-hydroxymethylcytosine and fragmentation signatures as enhanced biomarkers in lung cancer

Non-invasive Diagnosis of Nature of Pulmonary Nodules Using the Whole Genome Methylation Sequencing of Circulating Cell-Free DNA.

Diagnosis of Early-Stage Non-Small Cell Lung Cancer Using DNA Methylation in Tissue and Plasma

Multi-Dimensional Cell-free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer

Cell-free DNA 5-hydroxymethylcytosine profiles of long non-coding RNA genes enable early detection and progression monitoring of human cancers

Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum

Genome-wide Plasma Cell-Free DNA Methylation Profiling to Identify High-Performing Biomarkers for Early Detection of Hepatocellular Carcinoma.

Genome-wide Mapping of 5-Hydroxymethylcytosines in Circulating Cell-Free DNA As a Non-Invasive Approach for Early Detection of Hepatocellular Carcinoma

A 5-hydroxymethylcytosine-based non-invasive model for early detection of colorectal carcinomas and advanced adenomas: the METHOD-2 study